BiomX Inc. (NYSEAMERICAN:PHGE) Short Interest Down 26.1% in September

BiomX Inc. (NYSEAMERICAN:PHGE) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 370,300 shares, a decrease of 26.1% from the August 31st total of 501,400 shares. Approximately 2.7% of the company’s stock are short sold. Based on an average daily volume of 4,900,000 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 4,900,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.7% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of BiomX in a report on Wednesday, August 20th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.00.

BiomX Trading Up 6.0%

PHGE stock opened at $0.55 on Tuesday. The firm has a market cap of $14.58 million, a PE ratio of -0.40 and a beta of 1.45. BiomX has a 1 year low of $0.34 and a 1 year high of $1.16. The company has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.51.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).